Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25359262 | 1.00 | KMT2A (0.54) | KMT2ACASP3HDAC1HDAC2MDM4 | |
| SCHEMBL25359258 | 1.00 | KMT2A (0.54) | KMT2ACASP3HDAC1HDAC2MDM4 | |
| SCHEMBL26008676 | 1.00 | KMT2A (0.54) | KMT2ACASP3HDAC1HDAC2MDM4 | |
| SCHEMBL5061301 | 0.96 | KMT2A (0.58) | KMT2ACASP3HDAC1HDAC2MDM4 | |
| SCHEMBL29398585 | 0.94 | KMT2A (0.51) | KMT2ACASP3MDM4TP53CASP1 | |
| SCHEMBL29401691 | 0.94 | KMT2A (0.51) | KMT2ACASP3MDM4TP53CASP1 | |
| SCHEMBL10173082 | 0.94 | KMT2A (0.51) | KMT2ACASP3MDM4TP53CASP1 | |
| SCHEMBL15280776 | 0.94 | KMT2A (0.51) | KMT2ACASP3MDM4TP53CASP1 | |
| SCHEMBL30471287 | 0.94 | KMT2A (0.51) | KMT2ACASP3MDM4TP53CASP1 | |
| SCHEMBL28510322 | 0.94 | KMT2A (0.51) | KMT2ACASP3MDM4TP53CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131017-A1 | CD22 ANTIBODY AND DRUG CONJUGATES AND USES THEREOF | MEDIMMUNE LLC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4593885-B1 | CONJUGATES COMPRISING CLEAVABLE LINKERS | ASTRAZENECA AB (SE) | 2026-04-01 | — | — | EP | disclosed |
| EP-4601703-B1 | CONJUGATES COMPRISING CLEAVABLE LINKERS | ASTRAZENECA AB (SE) | 2026-03-25 | — | — | EP | disclosed |
| EP-4694936-A1 | STEAP2 ANTIBODY DRUG CONJUGATES AND USES THEREOF | MedImmune, LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025233501-A1 | CONJUGATES COMPRISING A TOPOISOMERASE I INHIBITOR | ASTRAZENECA AB (SE) | 2025-11-13 | — | — | WO | disclosed |
| US-12337038-B2 | Conjugates comprising cleavable beta-glucuronide-containing linkers | ASTRAZENECA AB (SE) | 2025-06-24 | — | — | US | disclosed |
| WO-2025032254-A1 | ANTHRACYCLINE DERIVATIVES AND CONJUGATES AND USES THEREOF | ASTRAZENECA AB (SE) | 2025-02-13 | — | — | WO | disclosed |
| US-20250041435-A1 | STEAP2 ANTIBODY DRUG CONJUGATES AND USES THEREOF | MEDIMMUNE, LLC | 2025-02-06 | — | — | US | disclosed |
| US-12178876-B2 | Conjugates comprising cleavable linkers | ASTRAZENECA, AB (SE) | 2024-12-31 | — | — | US | disclosed |
| US-20240366781-A1 | CONJUGATES COMPRISING CLEAVABLE LINKERS | ASTRAZENECA AB (SE) | 2024-11-07 | — | — | US | disclosed |
| US-20240366768-A1 | CONJUGATES COMPRISING CLEAVABLE LINKERS | ASTRAZENECA AB (SE) | 2024-11-07 | — | — | US | disclosed |
| WO-2024214028-A1 | STEAP2 ANTIBODY DRUG CONJUGATES AND USES THEREOF | MEDIMMUNE, LLC (US) | 2024-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041435-A1 | STEAP2 ANTIBODY DRUG CONJUGATES AND USES THEREOF | SPAG5, CD2BP2, SDAD1 | KMT2A 1216/4885CASP3 4157/4885HDAC1 4275/4885 |
| US-12337038-B2 | Conjugates comprising cleavable beta-glucuronide-containing linkers | GUSB, UGT2B7, UGT1A1 | KMT2A 3017/4885CASP3 1222/4885HDAC1 1042/4885 |
| US-20260131017-A1 | CD22 ANTIBODY AND DRUG CONJUGATES AND USES THEREOF | CD22, CD2, CD2BP2 | KMT2A 580/4885CASP3 2046/4885HDAC1 4607/4885 |
| US-12178876-B2 | Conjugates comprising cleavable linkers | PAICS, SI, CA14 | KMT2A 1367/4885CASP3 596/4885HDAC1 558/4885 |
| US-20240366781-A1 | CONJUGATES COMPRISING CLEAVABLE LINKERS | DHFR, SI, BCR | KMT2A 1577/4885CASP3 952/4885HDAC1 1151/4885 |
| US-20240366768-A1 | CONJUGATES COMPRISING CLEAVABLE LINKERS | PAICS, SI, CA14 | KMT2A 1367/4885CASP3 596/4885HDAC1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.